Methylthioninium, also known as methylene blue, is a synthetic compound originally developed in the late 19th century as a dye and later repurposed for medical use. It is primarily used in clinical medicine for the treatment of methemoglobinemia, where it acts as an electron carrier to restore hemoglobin’s ability to transport oxygen. Its history is marked by its transition from an industrial dye to an important emergency antidote in toxicology and hematology. Over time, methylthioninium has also been investigated for additional uses, including as a diagnostic stain and in experimental neurological and antimicrobial applications, with its clinical use guided by well-established safety and dosing protocols.
BRAND NAMES
ProvayBlue – FDA-approved sterile injectable form used for methemoglobinemia
Urolene Blue – older formulation used historically for urinary tract indications
Methylthioninium Chloride ProveBlue – another branded injectable preparation in some markets.
MECHANISM OF ACTION
Methylthioninium acts primarily as a redox agent. In the treatment of methemoglobinemia, it is reduced to leukomethylene blue, which then acts as an artificial electron carrier that converts methemoglobin (Fe³⁺) back to functional hemoglobin (Fe²⁺). This restores the oxygen-carrying capacity of blood. It also participates in redox cycling within cells, enhancing the activity of the NADPH-dependent methemoglobin reductase system.
PHARMACOKINETICS
Absorption
Methylthioninium is rapidly absorbed after intravenous administration, which is the primary route in emergency treatment. Oral absorption is variable and less predictable. Peak plasma concentrations occur quickly after IV dosing.
Distribution
It is widely distributed in body tissues and readily enters red blood cells, where it exerts its therapeutic effect. It can cross biological membranes and may accumulate in tissues to some extent.
Metabolism
It is metabolized in the liver and peripheral tissues to leukomethylene blue, its active reduced form, through enzymatic and non-enzymatic reduction processes.
Elimination
Excretion occurs mainly through the urine, where it imparts a characteristic blue-green discoloration. A smaller portion is eliminated via bile and feces. Elimination is relatively rapid after IV use.
PHARMACODYNAMICS
Methylthioninium functions as an electron donor/acceptor system that enhances cellular redox reactions. Its most important clinical effect is the rapid reduction of methemoglobin to hemoglobin via activation of the NADPH-dependent pathway. At low doses, it acts as a reducing agent, while at higher doses it may paradoxically act as an oxidant, worsening methemoglobinemia.
ADMINISTRATION
Methylthioninium is administered primarily by intravenous injection in emergency settings such as acute methemoglobinemia. It may also be used orally or via other routes in specialized or investigational settings, but IV administration is standard for rapid effect. Dosing is carefully controlled due to dose-dependent toxicity.
DOSAGE AND STRENGTH
Typical adult dosing for methemoglobinemia is 1–2 mg/kg intravenously over several minutes, with the possibility of repeating the dose if symptoms persist. Lower or adjusted doses are used in certain high-risk populations to avoid toxicity. Maximum cumulative dosing is strictly limited.
DRUG INTERACTIONS
Methylthioninium interacts significantly with serotonergic drugs such as SSRIs, SNRIs, and MAO inhibitors, increasing the risk of serotonin syndrome. It may also interact with drugs affecting NADPH pathways or redox systems. Caution is required with other oxidizing agents.
FOOD INTERACTIONS
Food has minimal effect on intravenous use. For oral formulations, food may slightly delay absorption but does not significantly alter overall effectiveness.
CONTRAINDICATIONS
It is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it may cause hemolysis. It should also be avoided in patients taking strong serotonergic medications due to risk of serotonin toxicity, and in severe renal impairment unless closely monitored.
SIDE EFFECTS
Common side effects include blue-green discoloration of urine, nausea, abdominal pain, dizziness, headache, and mild confusion. It may also cause transient hypertension or skin discoloration. High doses can paradoxically induce methemoglobinemia.
OVER DOSAGE
Overdose of Methylthioninium can be serious and is mainly dose-dependent and redox-mediated. At high doses, instead of reducing methemoglobin, it can paradoxically act as an oxidizing agent, worsening methemoglobinemia and leading to tissue hypoxia. Clinical features of overdose may include cyanosis, shortness of breath, confusion, headache, dizziness, and fatigue, along with blue-green discoloration of skin and urine.
TOXICITY
Toxicity of Methylthioninium is dose-dependent and may include worsening methemoglobinemia, hemolytic anemia (especially in G6PD deficiency), serotonin syndrome, confusion, and cardiovascular instability. Severe overdose can lead to neurological dysfunction and hypoxia. Management is supportive, with discontinuation of the drug and treatment of complications such as oxygen support or management of serotonin toxicity.
